Financial Review: Globus Medical (NYSE:GMED) vs. SeaStar Medical (NASDAQ:ICU)

Globus Medical (NYSE:GMED) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Globus Medical and SeaStar Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.48 billion	4.59	$122.87 million	$0.67	124.72
SeaStar Medical	$68,000.00	133.89	-$26.23 million	($11.63)	-0.18

Globus Medical has higher revenue and earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Globus Medical and SeaStar Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	1	2	9	0	2.67
SeaStar Medical	0	0	0	0	0.00

Globus Medical presently has a consensus target price of $94.55, indicating a potential upside of 13.15%. Given Globus Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Globus Medical is more favorable than SeaStar Medical.

Profitability

This table compares Globus Medical and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	3.69%	9.98%	7.92%
SeaStar Medical	N/A	N/A	-627.49%

Risk & Volatility

Globus Medical has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.

Insider & Institutional Ownership

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 18.5% of Globus Medical shares are held by insiders. Comparatively, 2.1% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Globus Medical beats SeaStar Medical on 13 of the 14 factors compared between the two stocks.

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.